{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T12:11:08Z","timestamp":1782994268074,"version":"3.54.5"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T00:00:00Z","timestamp":1614384000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T00:00:00Z","timestamp":1614384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["17-31754A"],"award-info":[{"award-number":["17-31754A"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007397","name":"Univerzita Karlova v Praze","doi-asserted-by":"publisher","award":["SVV 260 549"],"award-info":[{"award-number":["SVV 260 549"]}],"id":[{"id":"10.13039\/100007397","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Lipoprotein apheresis (LA) is considered as an add-on therapy for patients with familial hypercholesterolemia (FH). We aimed to analyze the data collected in the last 15\u00a0years from FH patients treated with LA, to elucidate the benefit of this procedure with respect to plasma lipids, biomarkers of inflammation, and endothelial dysfunction and soluble endoglin.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>14 patients (10 heterozygous FH patients (HeFH), 4 homozygous FH patients (HoFH)) were treated by long-term lipoprotein apheresis. Lipid levels were examined, and ELISA detected biomarkers of inflammation and soluble endoglin. Paired tests were used for intergroup comparisons, and a linear regression model served to estimate the influence of the number of days patients were treated with LA on the studied parameters. LA treatment was associated with a significant decrease of total cholesterol (TC), LDL-C, HDL-C, and apoB, in both HeFH and HoFH patients, after single apheresis and in a long-term period during the monitored interval of 15\u00a0years. Biomarkers of inflammation and endothelial dysfunction were reduced for soluble endoglin, hsCRP, and MCP-1, and sP-selectin after each procedure in some HeFH and HoFH patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>LA treatment up to 15\u00a0years, reduced cholesterol levels, levels of biomarkers related to endothelial dysfunction, and inflammation not only after each procedure but also in the long-term evaluation in FH patients. We propose that long-term LA treatment improves lipid profile and endothelial dysfunction in familial hypercholesterolemia patients, suggesting a promising improvement in cardiovascular prognosis in most FH patients.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13023-021-01749-w","type":"journal-article","created":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T12:02:56Z","timestamp":1614427376000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Monitoring of up to 15\u00a0years effects of lipoprotein apheresis on lipids, biomarkers of inflammation, and soluble endoglin in familial hypercholesterolemia patients"],"prefix":"10.1186","volume":"16","author":[{"given":"J.","family":"V\u00ed\u0161ek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bl\u00e1ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Bl\u00e1ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"L\u00e1\u0161ticov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"L\u00e1nska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Andr\u00fds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Duintjer","family":"Tebbens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivone Cristina","family":"Igreja e S\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Tripsk\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Vicen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Najmanov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9568-7295","authenticated-orcid":false,"given":"P.","family":"Nachtigal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,27]]},"reference":[{"key":"1749_CR1","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1016\/j.jacc.2020.03.058","volume":"75","author":"JJP Kastelein","year":"2020","unstructured":"Kastelein JJP, Reeskamp LF, Hovingh GK. Familial hypercholesterolemia: the most common monogenic disorder in humans. J Am Coll Cardiol. 2020;75:2567\u20139. https:\/\/doi.org\/10.1016\/j.jacc.2020.03.058.","journal-title":"J Am Coll Cardiol"},{"key":"1749_CR2","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s11883-014-0439-8","volume":"16","author":"M Abifadel","year":"2014","unstructured":"Abifadel M, Elbitar S, El Khoury P, et al. Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs. Curr Atheroscler Rep. 2014;16:439. https:\/\/doi.org\/10.1007\/s11883-014-0439-8.","journal-title":"Curr Atheroscler Rep"},{"key":"1749_CR3","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.atherosclerosis.2018.06.878","volume":"277","author":"F Alnouri","year":"2018","unstructured":"Alnouri F, Athar M, Al-Allaf FA, et al. Novel combined variants of LDLR and LDLRAP1 genes causing severe familial hypercholesterolemia. Atherosclerosis. 2018;277:425\u201333. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.06.878.","journal-title":"Atherosclerosis"},{"key":"1749_CR4","doi-asserted-by":"publisher","first-page":"363","DOI":"10.4070\/kcj.2013.43.6.363","volume":"43","author":"YR Kim","year":"2013","unstructured":"Kim YR, Han KH. Familial hypercholesterolemia and the atherosclerotic disease. Korean Circ J. 2013;43:363\u20137.","journal-title":"Korean Circ J"},{"key":"1749_CR5","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","volume":"34","author":"BG Nordestgaard","year":"2013","unstructured":"Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34:3478\u20133490a. https:\/\/doi.org\/10.1093\/eurheartj\/eht273.","journal-title":"Eur Heart J"},{"key":"1749_CR6","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1210\/jc.2015-3874","volume":"101","author":"A Cenarro","year":"2016","unstructured":"Cenarro A, Etxebarria A, de Castro-Or\u00f3s I, et al. The p. Leu167del mutation in APOE gene causes autosomal dominant hypercholesterolemia by down-regulation of LDL receptor expression in hepatocytes. J Clin Endocrinol Metab. 2016;101:2113\u201321.","journal-title":"J Clin Endocrinol Metab"},{"key":"1749_CR7","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.rec.2017.02.008","volume":"70","author":"F Civeira","year":"2017","unstructured":"Civeira F, Plana N. Treatment of heterozygous familial hypercholesterolemia in children and adolescents: an unsolved problem. Revista Espa\u00f1ola de Cardiolog\u00eda (Engl Ed). 2017;70:423\u20134. https:\/\/doi.org\/10.1016\/j.rec.2017.02.008.","journal-title":"Revista Espa\u00f1ola de Cardiolog\u00eda (Engl Ed)"},{"key":"1749_CR8","doi-asserted-by":"crossref","unstructured":"Creider J, Hegele R. Clinical evaluation for genetic and secondary causes of dyslipidemia. In: Elsevier (ed) Clinical lipidology, 2nd ed. Philadelphia (USA), 2015, p. 128\u201334.","DOI":"10.1016\/B978-0-323-28786-9.00011-6"},{"key":"1749_CR9","doi-asserted-by":"crossref","unstructured":"Bambauer R, Bambauer C, Lehmann B, et al. LDL-apheresis: technical and clinical aspects. Sci World J; 2012.","DOI":"10.1100\/2012\/314283"},{"key":"1749_CR10","doi-asserted-by":"publisher","first-page":"S91","DOI":"10.33549\/physiolres.933584","volume":"66","author":"V Blaha","year":"2017","unstructured":"Blaha V, Blaha M, Lanska M, et al. Lipoprotein apheresis in the treatment of dyslipidemia\u2013the Czech Republic Experience. Physiol Res. 2017;66:S91.","journal-title":"Physiol Res"},{"key":"1749_CR11","doi-asserted-by":"publisher","first-page":"3634","DOI":"10.2174\/1381612824666181025115658","volume":"24","author":"C Stefanutti","year":"2018","unstructured":"Stefanutti C, Zenti MG. Lipoprotein apheresis and PCSK9-inhibitors. Impact on atherogenic lipoproteins and anti-inflammatory mediators in familial hypercholesterolaemia. Curr Pharm Des. 2018;24:3634\u20137.","journal-title":"Curr Pharm Des"},{"key":"1749_CR12","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.atherosclerosissup.2017.05.002","volume":"30","author":"V Blaha","year":"2017","unstructured":"Blaha V, Blaha M, Solichova D, et al. Antioxidant defense system in familial hypercholesterolemia and the effects of lipoprotein apheresis. Atheroscler Suppl. 2017;30:159\u201365.","journal-title":"Atheroscler Suppl"},{"key":"1749_CR13","first-page":"20","volume":"9","author":"GV Chepelenko","year":"2003","unstructured":"Chepelenko GV. Pathogenesis of atherosclerosis in patients with lipid metabolism disturbances: hypothesis on cholesterol utilization and atheromatous plaque formation. Angiol Sosud Khir. 2003;9:20\u20135.","journal-title":"Angiol Sosud Khir"},{"key":"1749_CR14","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1902\/jop.2008.080249","volume":"79","author":"PM Ridker","year":"2008","unstructured":"Ridker PM, Silvertown JD. Inflammation, C-reactive protein, and atherothrombosis. J Periodontol. 2008;79:1544\u201351. https:\/\/doi.org\/10.1902\/jop.2008.080249.","journal-title":"J Periodontol"},{"key":"1749_CR15","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1081\/IMM-120037275","volume":"33","author":"M Hajilooi","year":"2004","unstructured":"Hajilooi M, Sanati A, Ahmadieh A, et al. Circulating ICAM-1, VCAM-1, E-selectin, P-selectin, and TNFRII in patients with coronary artery disease. Immunol Invest. 2004;33:263\u201375.","journal-title":"Immunol Invest"},{"key":"1749_CR16","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s004280000215","volume":"437","author":"MJ Szabolcs","year":"2000","unstructured":"Szabolcs MJ, Cannon PJ, Thienel U, et al. Analysis of CD154 and CD40 expression in native coronary atherosclerosis and transplant associated coronary artery disease. Virchows Arch. 2000;437:149\u201359.","journal-title":"Virchows Arch"},{"key":"1749_CR17","doi-asserted-by":"crossref","first-page":"273","DOI":"10.33549\/physiolres.930460","volume":"53","author":"M Blaha","year":"2004","unstructured":"Blaha M, Krejsek J, Blaha V, et al. Selectins and monocyte chemotactic peptide as the markers of atherosclerosis activity. Physiol Res. 2004;53:273\u20138.","journal-title":"Physiol Res"},{"key":"1749_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/biom10020289","author":"MJA Schoonderwoerd","year":"2020","unstructured":"Schoonderwoerd MJA, Goumans MTH, Hawinkels L. Endoglin: beyond the endothelium. Biomolecules. 2020. https:\/\/doi.org\/10.3390\/biom10020289.","journal-title":"Biomolecules"},{"key":"1749_CR19","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/0021-9150(95)05713-7","volume":"120","author":"AD Blann","year":"1996","unstructured":"Blann AD, Wang JM, Wilson PB, et al. Serum levels of the TGF-beta receptor are increased in atherosclerosis. Atherosclerosis. 1996;120:221\u20136.","journal-title":"Atherosclerosis"},{"key":"1749_CR20","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.atherosclerosis.2007.04.022","volume":"197","author":"M Blaha","year":"2008","unstructured":"Blaha M, Cermanova M, Blaha V, et al. Elevated serum soluble endoglin (sCD105) decreased during extracorporeal elimination therapy for familial hypercholesterolemia. Atherosclerosis. 2008;197:264\u201370. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2007.04.022.","journal-title":"Atherosclerosis"},{"key":"1749_CR21","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201802245R","author":"M Vicen","year":"2019","unstructured":"Vicen M, Vitverova B, Havelek R, et al. Regulation and role of endoglin in cholesterol-induced endothelial and vascular dysfunction in vivo and in vitro. FASEB J. 2019. https:\/\/doi.org\/10.1096\/fj.201802245R.","journal-title":"FASEB J"},{"key":"1749_CR22","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1253\/circj.CJ-10-1285","volume":"75","author":"Z Strasky","year":"2011","unstructured":"Strasky Z, Vecerova L, Rathouska J, et al. Cholesterol effects on endoglin and its downstream pathways in ApoE\/LDLR double knockout mice. Circ J. 2011;75:1747\u201355.","journal-title":"Circ J"},{"key":"1749_CR23","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.phrs.2011.03.008","volume":"64","author":"J Rathouska","year":"2011","unstructured":"Rathouska J, Vecerova L, Strasky Z, et al. Endoglin as a possible marker of atorvastatin treatment benefit in atherosclerosis. Pharmacol Res. 2011;64:53\u20139. https:\/\/doi.org\/10.1016\/j.phrs.2011.03.008.","journal-title":"Pharmacol Res"},{"key":"1749_CR24","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.08.014","volume":"290","author":"F Mach","year":"2019","unstructured":"Mach F, Baigent C, Catapano AL, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019;290:140\u2013205.","journal-title":"Atherosclerosis"},{"key":"1749_CR25","doi-asserted-by":"publisher","unstructured":"Adults EPoDEaToHBCi. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA: J Am Med Assoc. 2001;285: 2486\u201397. https:\/\/doi.org\/10.1001\/jama.285.19.2486.","DOI":"10.1001\/jama.285.19.2486"},{"key":"1749_CR26","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/14656566.2018.1550071","volume":"20","author":"JS Parham","year":"2019","unstructured":"Parham JS, Goldberg AC. Mipomersen and its use in familial hypercholesterolemia. Expert Opin Pharmacother. 2019;20:127\u201331. https:\/\/doi.org\/10.1080\/14656566.2018.1550071.","journal-title":"Expert Opin Pharmacother"},{"key":"1749_CR27","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1177\/2047487317734387","volume":"24","author":"E Bruckert","year":"2017","unstructured":"Bruckert E, Gallo A. Is lomitapide a life-saving drug in homozygous familial hypercholesterolemia. Eur J Prev Cardiol. 2017;24:1841\u20132. https:\/\/doi.org\/10.1177\/2047487317734387.","journal-title":"Eur J Prev Cardiol"},{"key":"1749_CR28","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/s0021-9150(00)00371-3","volume":"152","author":"AA Kroon","year":"2000","unstructured":"Kroon AA, Van\u2019Hof MA, Demacker PN, et al. The rebound of lipoproteins after LDL-apheresis Kinetics and estimation of mean lipoprotein levels. Atherosclerosis. 2000;152:519\u201326. https:\/\/doi.org\/10.1016\/s0021-9150(00)00371-3.","journal-title":"Atherosclerosis"},{"key":"1749_CR29","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.atherosclerosis.2018.08.007","volume":"277","author":"S Beliard","year":"2018","unstructured":"Beliard S, Gallo A, Duchene E, et al. Lipoprotein-apheresis in familial hypercholesterolemia: Long-term patient compliance in a French cohort. Atherosclerosis. 2018;277:66\u201371. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.08.007.","journal-title":"Atherosclerosis"},{"key":"1749_CR30","doi-asserted-by":"publisher","first-page":"976578","DOI":"10.1155\/2012\/976578","volume":"2012","author":"G Kolovou","year":"2012","unstructured":"Kolovou G, Hatzigeorgiou G, Mihas C, et al. Changes in lipids and lipoproteins after selective LDL apheresis (7-year experience). Cholesterol. 2012;2012:976578. https:\/\/doi.org\/10.1155\/2012\/976578.","journal-title":"Cholesterol"},{"key":"1749_CR31","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1046\/j.1526-0968.2003.00073.x","volume":"7","author":"H Makino","year":"2003","unstructured":"Makino H, Harada-Shiba M. Long-term effect of low-density lipoprotein apheresis in patients with homozygous familial hypercholesterolemia. Therapeutic Apher Dial. 2003;7:397\u2013401. https:\/\/doi.org\/10.1046\/j.1526-0968.2003.00073.x.","journal-title":"Therapeutic Apher Dial"},{"key":"1749_CR32","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1536\/ihj.46.833","volume":"46","author":"N Masaki","year":"2005","unstructured":"Masaki N, Tatami R, Kumamoto T, et al. Ten-year follow-up of familial hypercholesterolemia patients after intensive cholesterol-lowering therapy. Int Heart J. 2005;46:833\u201343. https:\/\/doi.org\/10.1536\/ihj.46.833.","journal-title":"Int Heart J"},{"key":"1749_CR33","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1194\/jlr.P016816","volume":"52","author":"A Orsoni","year":"2011","unstructured":"Orsoni A, Saheb S, Levels JH, et al. LDL-apheresis depletes apoE-HDL and pre-beta1-HDL in familial hypercholesterolemia: relevance to atheroprotection. J Lipid Res. 2011;52:2304\u201313. https:\/\/doi.org\/10.1194\/jlr.P016816.","journal-title":"J Lipid Res"},{"key":"1749_CR34","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.atherosclerosissup.2012.10.017","volume":"14","author":"CL Neumann","year":"2013","unstructured":"Neumann CL, Schulz EG, Hagenah GC, et al. Lipoprotein apheresis \u2013 More than just cholesterol reduction? Atheroscler Suppl. 2013;14:29\u201332. https:\/\/doi.org\/10.1016\/j.atherosclerosissup.2012.10.017.","journal-title":"Atheroscler Suppl"},{"key":"1749_CR35","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1253\/circj.CJ-08-1102","volume":"73","author":"Y Higashi","year":"2009","unstructured":"Higashi Y, Noma K, Yoshizumi M, et al. Endothelial function and oxidative stress in cardiovascular diseases. Circ J. 2009;73:411\u20138.","journal-title":"Circ J"},{"key":"1749_CR36","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1016\/j.jacc.2014.01.088","volume":"64","author":"DF van Wijk","year":"2014","unstructured":"van Wijk DF, Sjouke B, Figueroa A, et al. Nonpharmacological lipoprotein apheresis reduces arterial inflammation in familial hypercholesterolemia. J Am Coll Cardiol. 2014;64:1418\u201326. https:\/\/doi.org\/10.1016\/j.jacc.2014.01.088.","journal-title":"J Am Coll Cardiol"},{"key":"1749_CR37","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.cca.2006.09.026","volume":"377","author":"K Utsumi","year":"2007","unstructured":"Utsumi K, Kawabe M, Hirama A, et al. Effects of selective LDL apheresis on plasma concentrations of ICAM-1, VCAM-1 and P-selectin in diabetic patients with arteriosclerosis obliterans and receiving maintenance hemodialysis. Clin Chim Acta. 2007;377:198\u2013200. https:\/\/doi.org\/10.1016\/j.cca.2006.09.026.","journal-title":"Clin Chim Acta"},{"key":"1749_CR38","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.1744-9987.2006.00332.x","volume":"10","author":"S Kobayashi","year":"2006","unstructured":"Kobayashi S, Oka M, Moriya H, et al. LDL-apheresis reduces P-Selectin, CRP and fibrinogen \u2013 possible important implications for improving atherosclerosis. Ther Apher Dial. 2006;10:219\u201323. https:\/\/doi.org\/10.1111\/j.1744-9987.2006.00332.x.","journal-title":"Ther Apher Dial"},{"key":"1749_CR39","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1161\/01.CIR.96.5.1381","volume":"96","author":"T Sampietro","year":"1997","unstructured":"Sampietro T, Tuoni M, Ferdeghini M, et al. Plasma cholesterol regulates soluble cell adhesion molecule expression in familial hypercholesterolemia. Circulation. 1997;96:1381\u20135.","journal-title":"Circulation"},{"key":"1749_CR40","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/jca.10010","volume":"17","author":"K Empen","year":"2002","unstructured":"Empen K, Otto C, Br\u00f6dl UC, et al. The effects of three different LDL-apheresis methods on the plasma concentrations of E-selectin, VCAM-1, and ICAM-1. J Clin Apher. 2002;17:38\u201343.","journal-title":"J Clin Apher"},{"key":"1749_CR41","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1046\/j.1526-0968.2002.00405.x","volume":"6","author":"E Pulawski","year":"2002","unstructured":"Pulawski E, Mellwig KP, Brinkmann T, et al. Influence of single low-density lipoprotein apheresis on the adhesion molecules soluble vascular cellular adhesion molecule-1, soluble intercellular adhesion molecule-1, and P-selectin. Ther Apher. 2002;6:229\u201333.","journal-title":"Ther Apher"},{"key":"1749_CR42","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.atherosclerosissup.2017.05.037","volume":"30","author":"D Dlouha","year":"2017","unstructured":"Dlouha D, Blaha M, Blaha V, et al. analysis of circulating miRNAs in patients with familial hypercholesterolaemia treated by LDL\/Lp(a) apheresis. Atheroscler Suppl. 2017;30:128\u201334. https:\/\/doi.org\/10.1016\/j.atherosclerosissup.2017.05.037.","journal-title":"Atheroscler Suppl"},{"key":"1749_CR43","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.atherosclerosis.2015.10.003","volume":"243","author":"J Rathouska","year":"2015","unstructured":"Rathouska J, Jezkova K, Nemeckova I, et al. Soluble endoglin, hypercholesterolemia and endothelial dysfunction. Atherosclerosis. 2015;243:383\u20138. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2015.10.003.","journal-title":"Atherosclerosis"},{"key":"1749_CR44","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/1741-7015-8-86","volume":"8","author":"AM Blazquez-Medela","year":"2010","unstructured":"Blazquez-Medela AM, Garcia-Ortiz L, Gomez-Marcos MA, et al. Increased plasma soluble endoglin levels as an indicator of cardiovascular alterations in hypertensive and diabetic patients. BMC Med. 2010;8:86. https:\/\/doi.org\/10.1186\/1741-7015-8-86.","journal-title":"BMC Med"},{"key":"1749_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/cells9040988","author":"E Gallardo-Vara","year":"2020","unstructured":"Gallardo-Vara E, Gamella-Pozuelo L, Perez-Roque L, et al. Potential role of circulating endoglin in hypertension via the upregulated expression of BMP4. Cells. 2020. https:\/\/doi.org\/10.3390\/cells9040988.","journal-title":"Cells"},{"key":"1749_CR46","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.atherosclerosis.2018.02.008","volume":"271","author":"B Vitverova","year":"2018","unstructured":"Vitverova B, Blazickova K, Najmanova I, et al. Soluble endoglin and hypercholesterolemia aggravate endothelial and vessel wall dysfunction in mouse aorta. Atherosclerosis. 2018;271:15\u201325. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.02.008.","journal-title":"Atherosclerosis"},{"key":"1749_CR47","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.atherosclerosissup.2017.05.037","volume":"30","author":"D Dlouha","year":"2017","unstructured":"Dlouha D, Blaha M, Blaha V, et al. analysis of circulating miRNAs in patients with familial hypercholesterolaemia treated by LDL\/Lp (a) apheresis. Atherosclerosis Supplements. 2017;30:128\u201334.","journal-title":"Atherosclerosis Supplements"},{"key":"1749_CR48","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jacl.2019.02.003","volume":"13","author":"H Vaverkova","year":"2019","unstructured":"Vaverkova H, Tichy L, Karasek D, et al. A case of autosomal recessive hypercholesterolemia caused by a new variant in the LDL receptor adaptor protein 1 gene. J Clin Lipidol. 2019;13:405\u201310.","journal-title":"J Clin Lipidol"},{"key":"1749_CR49","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1744-9987.2007.00450.x","volume":"11","author":"M Blaha","year":"2007","unstructured":"Blaha M, Cermanova M, Blaha V, et al. Safety and tolerability of long lasting LDL-apheresis in familial hyperlipoproteinemia. Ther Apher Dial. 2007;11:9\u201315. https:\/\/doi.org\/10.1111\/j.1744-9987.2007.00450.x.","journal-title":"Ther Apher Dial"},{"key":"1749_CR50","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S0009-9120(01)00261-2","volume":"34","author":"D Solichova","year":"2001","unstructured":"Solichova D, Melichar B, Blaha V, et al. Biochemical profile and survival in nonagenarians. Clin Biochem. 2001;34:563\u20139.","journal-title":"Clin Biochem"},{"key":"1749_CR51","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.atherosclerosissup.2012.10.019","volume":"14","author":"M Blaha","year":"2013","unstructured":"Blaha M, Kostal M, Lanska M, et al. The decrease of mean platelet volume after extracorporeal LDL-cholesterol elimination. Atheroscler Suppl. 2013;14:77\u201381. https:\/\/doi.org\/10.1016\/j.atherosclerosissup.2012.10.019.","journal-title":"Atheroscler Suppl"},{"key":"1749_CR52","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S1567-5688(09)71804-5","volume":"10","author":"M Blaha","year":"2009","unstructured":"Blaha M, Zadak Z, Blaha V, et al. Extracorporeal LDL cholesterol elimination (25 years of experience in CZ). Atheroscler Suppl. 2009;10:17\u201320. https:\/\/doi.org\/10.1016\/S1567-5688(09)71804-5.","journal-title":"Atheroscler Suppl"},{"key":"1749_CR53","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.transci.2003.11.002","volume":"30","author":"M Blaha","year":"2004","unstructured":"Blaha M, Pecka M, Urbankova J, et al. Activity of thrombocytes as a marker of sufficient intensity of LDL-apheresis in familial hypercholesterolaemia. Transfus Apher Sci. 2004;30:83\u20137. https:\/\/doi.org\/10.1016\/j.transci.2003.11.002.","journal-title":"Transfus Apher Sci"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01749-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-021-01749-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01749-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T23:51:09Z","timestamp":1724543469000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-021-01749-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,27]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1749"],"URL":"https:\/\/doi.org\/10.1186\/s13023-021-01749-w","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,27]]},"assertion":[{"value":"1 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The protocol was carried out according to the Declaration of Helsinki. All examined individuals were Caucasians, and all signed informed consent forms, which, together with the protocol of the study, were approved by the institute's ethics committee Faculty hospital in Hradec Kralove.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Available upon request.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None of the authors have a financial relationship with a commercial entity interested in the subject of the presented manuscript or other conflicts of interest to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"110"}}